Approximately 13% of approved drugs have mechanisms involving the modulation of ion channel activity, which makes ion channels the second-largest mechanistic class of marketed compounds.

1. Advances in Ion Channel Drug Discovery
Approximately 13% of approved drugs have mechanisms involving the modulation of ion
channel activity, which makes ion channels the second-largest mechanistic class of
marketed compounds. Currently approved drugs address important disease areas including
diabetes, epilepsy, hypertension, cardiac arrhythmia, anxiety, and pain.
Approximately 35% of agents in development have big pharma sponsorship, with the
remaining 65% under development by smaller biotech. CNS indications account for 45% of
development programs. Agents in late-stage development include several first-in-class
agents acting at the cystic fibrosis transmembrane regulator, and new NMDA and AMPA
antagonists.
Earlier-stage programs focus on selective Nav blockers (following on from genetic validation
of Nav1.7 involvement in pain), subtype-selective NMDA and AMPA blockers, and a large
number of TRP family members for a variety of indications.
Request a Sample for or Inquire before buying the report Ion Channel Drug
Discovery
Features and benefits
 Understand the competitive landscape in ion channel modulation and compare the pipelines
of specialist companies operating in this area
 Identify the most promising targets from a "likelihood of success" viewpoint.
 Identify the targets with scope for ion channel intervention and major market opportunity.
 Understand which advances in target discovery, technology, and clinical development will
have biggest impact to move the area forward.
 Benchmark available technologies against the gold standard for ion channel discovery.
Major points covered in Table of Contents of this report include:
EXECUTIVE SUMMARY
Introduction
Characteristics of ion channels
Commercial exploitation
Discovery approaches
New opportunities

2. Specialist company profiles
Outlook
Appendix
List of Tables
List of Figures
Report Details:
Published: March 2012
No. of Pages: 194
Price: Single User License – US$3835 Corporate User License – US$14381
Contact:
Priyank Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252.
Tel: +1-888-391-5441
sales@reportsandreports.com
Visit our Market Research Blog @ http://www.reportsnreportsblog.com/
Connect With Us: